North America High Resolution Melting Analysis Market

North America High-Resolution Melting Analysis Market Size (2023 to 2028)

The size of the High-Resolution Melting Analysis Market in North America is valued at USD 77.83 million in 2023. This value is projected to be growing at a CAGR of 3.8%, to touch USD 93.79 million by 2028.

Increasing R&D investments, increasing applications of this technology in epigenetics, and digitization of mutations are some of the growth factors of the market. Benefits such as no probe, closed tube system, prevention of contamination of post-PCR samples, and high precision of fusion profile analysis drive the growth of the fusion analysis market at high resolution. The technology used in manufacturing, the quality of the product, and the ability to process samples are the main variables that can affect these products' usage rates. Increased collaboration between government agencies and key players to introduce technologically advanced products and reduce overall healthcare costs is expected to intensify competition in the high-resolution fusion analysis market.

Additionally, factors such as the increasing prevalence of chronic diseases, increasing demand for personalized medicine, and supportive government initiatives are expected to impact the high-resolution fusion market analysis market positively. Also, the growing incidence of infectious diseases and genetic disorders, the popularity of personalized medicine, and the increasing awareness of conventional systems' limitations compared to high-resolution fusion are other important factors driving the growth of the market.

A technical limitation associated with HRM-QPCR analysis, data storage issues, and low cost of other genotyping technologies hinder the market growth.

This research report on North America High-Resolution Melting Analysis Market has been segmented and sub-segmented into the following categories:

• By Product and Service: Instruments, Reagents and Consumables, Software And Services.
• By Application: Mutation Discovery, SNP Genotyping, Species Identification, Pathogen Identification, Epigenetics.
• By End User: Pharmaceutical and Biotechnology Companies, Research Laboratories And Academic Institutes, Hospitals And Diagnostic Centers.
• By Country: The United States, Canada and Rest of North America.

Regional Analysis:

North America took the major chunk of the global high-resolution melting analysis market share in 2019, with the U.S. accounting for a major share. Swift introduction of new technologies driven by the increasing incidence of genetic abnormalities due to the expanding populace and increasing elderly population are driving the North American High-Resolution Melting Analysis Market.

In this region, the United States has the highest share due to supportive healthcare policies, increased patient numbers, and a developed health care market. High-resolution fusion analysis is likely to have a successful future due to ongoing research and development in this field sponsored by several leading companies operating in this particular field. For example, the United States FDA approves many treatments designed to treat a specific genomic profile or genetic makeup of the patient's tumor. Recent developments in next-generation sequencing (NGS), genomics, and big data analysis have contributed to strengthening the approach to precision medicine. The US FDA has previously discussed several treatment options designed to meet a patient's specific tumor genetic makeup or genomic profile requirements. This, in turn, is expected to drive the demand for high-resolution fusion analysis over the forecast period.

Prominent Companies leading the North America High-Resolution Melting Analysis Market Profiled in the Report are Thermo Fisher Scientific Inc. (U.S.), F. Hofmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories (U.S.), and QIAGEN N.V. (Netherlands). Other players in the market include Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Illumina, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Novacyt (France), Azura Genomics (U.S.), Canon Biomedical (U.S.), and PREMIER Biosoft (U.S.), among others.